This page was printed from the South & West Devon Formulary and Referral site at
Please ensure you are using the current version of this document
National Patient Safety Agency (NPSA) Rapid response alert - Risks of incorrect dosing of oral anti-cancer medicine (January 2008)
This alert is only focusing on patients who receive treatment for a malignancy. It does not include patients who receive cytotoxics for treatment of rheumatoid arthritis or other auto-immune diseases.
The NPSA is alerting all healthcare staff involved in the use of oral anti-cancer medicines of potentially fatal outcomes if incorrect doses of these medicines are used. Oral anti-cancer medicines are increasingly being used in hospitals and in the community. Risks are increased if non-specialist practitioners prescribe, dispense or administer these oral medicines and bypass the normal safeguards used for injectable anti-cancer medicines.
Home > Formulary > Chapters > 8. Immunomodulatory treatments and malignant disease > 8.1 Cytotoxic drugs